The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation

Kidney International

Volumn 72, Issue 8, 2007, Pages 1014-1022

  Dmitrienko, S ^a   Yu, A ^a   Balshaw, R ^a   Shapiro, R J ^a   Keown, P A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Gordon and Leslie Diamond Health Care Centre Vancouver Coastal Health   (Canada)

Author keywords

Antiviral therapy; Cost analysis; Cytomegalovirus; Kidney transplantation; Predictive value

Indexed keywords

CYTOMEGALOVIRUS PP65 PROTEIN; GANCICLOVIR; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONSENSUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HEALTH CARE; HEALTH CARE COST; HUMAN; INCIDENCE; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; PROTEIN EXPRESSION;

ADULT; ANTIVIRAL AGENTS; CANADA; COHORT STUDIES; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GANCICLOVIR; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; VIRAL MATRIX PROTEINS;

EID: 34948905284     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002464     Document Type: Article

References (61)

1. Keay S. CMV infection and disease in kidney and pancreas transplant recipients. Transpl Infect Dis 1991; 1(Suppl 1): 19-24.
2. Brennan D. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001; 12: 848-855.
3. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-856.
4. Toupance O, Bouedjoro-Camus MC, Carquin J et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transplant Int 2000; 13: 413-419.
5. Reischig T, Jindra P, Svecova M et al. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 2006; 36: 146-151.
6. Tong C, Bakran A, Peiris J et al. The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation. Transplantation 2002; 74: 576-578.
7. Schnitzler MA. Costs and consequences of cytomegalovirus disease. Am J Health Syst Pharm 2003; 60: S5-S8.
8. Nett P, Heisey D, Fernandez L et al. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78: 1036-1041.
9. McCarthy J, Karim M, Krueger H et al. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993; 55: 1277-1282.
10. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 928-936.
11. Drummer S. Controlling the Troll: management of cytomegalovirus infection after transplantation. Ann Int Med 2005; 143: 913-914.
12. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143.
13. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 73-81.
14. Emery V. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83-86.
15. Koetz AC, Delbruck R, Furtwangler A et al. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study. Transplantation 2001; 72: 1325-1327.
16. Strippoli GFM, Hodson EM, Jones C et al. Pre-emptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139-145.
17. Brennan DC, Garlock KA, Lippmann BA et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118-125.
18. Kalil A, Levitsky J, Lyden E et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Int Med 2005; 143: 870-880.
19. Couchoud C, Cucherat M, Haugh M et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998; 65: 641-647.
20. Preiksaitis J, Brennan D, Fishman J et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218-227.
21. Akobeng A. Principles of evidence based medicine. Arch Dis Child 2005; 90: 837-840.
22. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 1462-1470.
23. Balfour H, Chace B, Stapleton J et al. A randomized, placebo-contolled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381-1387.
24. Verheyden JP. Evolution of therapy for cytomegalovirus infection. Rev Inf Dis 1988; 10(Suppl 3): S477-S489.
25. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T et al. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000; 70: 1174-1180.
26. Lake K. New prophylactic treatment strategy for cytomegalovirus disease. Am J Health Syst Pharm 2003; 60: S13-S16.
27. Kletzmayr J, Kotzmann H, Popow-Kraupp T et al. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325-330.
28. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
29. Ketteler M, Kunter U, Floege J. An update on herpes virus infections in graft recipients. Nephrol Dial Transplant 2003; 18: 1703-1706.
30. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
31. Taber D, Ashcraft E, Baillie G et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004; 6: 101-109.
32. Uknis ME. Prophylaxis of cytomegalovirus disease in transplant patients. Am J Health Syst Pharm 2005; 62: S3-S6.
33. Sagedal S, Nordal KP, Hartmann A et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899-1908.
34. Brennan D, Garlock K, Singer G et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843-1846.
35. Hibberd P, Snydman D. Cytomegalovirus infection in organ transplant recipients. Inf Dis Clin North Am 1995; 9: 863-877.
36. Rubin R. Infection in the organ transplant recipient. In: Rubin R, Young L (eds). Clinical Approach to Infection in the Compromised Host, 3rd edn, Plenum Press: New York, 1994, pp 629-705.
37. Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166-1174.
38. Abbott K, Hypolite I, Viola R et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 2002; 12: 402-409.
39. Wright Jr FH, Banowsky LH. Cytomegalovirus infection and prophylaxis in renal transplantation: financial considerations. Transplant Proc 1998; 30: 1318-1319.
40. Gabardi S, Magee C, Baroletti S et al. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004; 24: 1323-1330.
41. Murray B, Subramaniam S. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Transpl Infect Dis 2004; 6: 3-9.
42. McLaughlin K, Sandhu S, Muirhead N et al. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival. Nephrol Dialysis Transplant 2005; 20: 176-180.
43. Humar A, Kumar D, Boivin G et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Inf Dis 2002; 186: 829.
44. Singh N. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war? Eur J Clin Microbiol Infect Dis 2002; 21: 902.
45. Doyle A, Warburton K, Goral S et al. 24-Week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106-1111.
46. Tong C, Cuevas L, Williams H et al. Use of laboratory assays to predict cytomegalovirus disease in renal transplant recipients. J Clin Microbiol 1998; 36: 2681-2685.
47. Tong C, Cuevas L, Williams H et al. Prediction and diagnosis of cytomegalovirus disease in renal transplant recipients using qualitative and quantitative polymerase chain reaction. Transplantation 2000; 69: 985-991.
48. Kim C, Song J-H, Kim S-M et al. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation. Transplantation 2003; 75: 2151-2155.
49. Hassan-Walker I, Kidd I, Sabin C et al. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 1999; 58: 182-187.
50. Meyer-Koenig U, Weidmann M, Kirste G et al. Cytomegalovirus infection in organ-transplant recipients: diagnostic value of pp65 antigen test, qualitative polymerase chain reaction (PCR) and quantitative Taqman PCR. Transplantation 2004; 77: 1692-1698.
51. Bernabeu-Wittel M, Pachon-Ibanez J, Cisneros J et al. Quantitative pp65 antigenemia in the diagnosis of cytomegalovirus disease: prospective assessment in a cohort of solid organ transplant recipients. J Infect 2005; 51: 188-194.
52. Schroeder R, Michelon T, Fagundes I et al. Antigenemia for cytomegalovirus in renal transplantation: choosing a cutoff for the diagnosis criteria in cytomegalovirus disease. Transplant Proc 2005; 37: 2781-2783.
53. Hagenmeyer EG, Haussler B, Hempel E et al. Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications. Transplantation 2004; 77: 1545-1550.
54. Tilden D, Chapman J, Davey P et al. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. Clin Transplant 2004; 18: 312-320.
55. Keown PA. New immunosuppressive strategies. Curr Opin Nephrol Hypertens 1998; 7: 659-663.
56. Buhaescu I, Segall L, Goldsmith D et al. New immunosuppressive therapies in renal transplantation: monoclonal antibodies. J Nephrol 2005; 18: 529-536.
57. Woodroffe R, Yao G, Meads C et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005; 9: 1-194.
58. Keown PA, Kiberd B, Balshaw R et al. An economic model of two-hour post-dose cyclosporine monitoring in renal transplantation. Pharmacoeconomics 2004; 22: 621-632.
59. Keown PA, Balshaw R, Krueger H et al. An economic model of Simulect in renal transplantation. Transplantation 2001; 71: 1573-1579.
60. Schechter MT, Sheps SB. Diagnostic testing revisited: pathways through uncertainty. CMAJ 1985; 132: 755.
61. LaBaer J. So, you want to look for biomarkers. J Proteome Res 2005; 4: 1053-1059.